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abstract: Objectives: This study aimed to evaluate cardiovascular complications among patients who abuse 
amphetamines. Methods: This cross-sectional study took place between April 2014 and April 2015 among 3,870 
patients referred to the Toxicology Emergency Department of Baharlou Hospital, Tehran University of Medical 
Sciences, Tehran, Iran. Those with clinical signs of drug abuse and positive urine screening tests were included in the 
study, while cases of chronic abuse were excluded. Cardiac complications were evaluated via electrocardiography 
(ECG) and transthoracic echocardiography. Results: A total of 230 patients (5.9%) had a history of acute 
amphetamine abuse and positive urine tests. Of these, 32 patients (13.9%) were <20 years old and 196 (85.2%) 
were male. In total, 119 (51.7%) used amphetamine and methamphetamine compounds while 111 (48.3%) used 
amphetamines with morphine or benzodiazepines. The most common ECG finding was sinus tachycardia (43.0%), 
followed by sinus tachycardia plus a prolonged QT interval (34.3%). Mean creatine kinase-MB and troponin I 
levels were 35.9 ± 4.3 U/mL and 0.6 ± 0.2 ng/mL, respectively. A total of 60 patients (26.1%) were admitted to the 
Intensive Care Unit. The majority (83.3%) of these patients had normal echocardiography results. The mean aortic 
root diameter (ARD) was 27.2 ± 2.8 mm. Abnormalities related to the ARD were found in 10 patients (16.7%), three 
of whom subsequently died. Conclusion: According to these findings, cardiac complications were common among 
Iranian patients who abuse amphetamines, although the majority of patients had normal echocardiography and 
ECG findings.
Keywords: Amphetamines; Substance Abuse; Cardiovascular Abnormalities; Tachycardia; Echocardiography; 
Electrocardiography; Iran.
اإىل تقييم م�ضاعفات جهاز القلب واالأوعية الدم�ية لدى املر�ضى الذين يتعاط�ن االأمفيتامينات.  الهدف: هدفت هذه الدرا�ضة  امللخ�ص: 
الطريقة: متت هذة الدرا�ضة امل�ضتعر�ضة يف الفرتة ما بني اأبريل 2014 واأبريل 2015 وت�ضمنت 3,870 مري�ضًا مت حت�يلهم اإىل ق�ضم ط�ارئ 
ال�ضم�م يف م�ضت�ضفى باهارل� بجامعة طهران للعل�م الطبية باإيران. وقد مت قب�ل املر�ضى يف هذه الدرا�ضة اإذا كان لديهم عالمات �رسيرية 
لتعاطي املخدرات وفح��ضات اإيجابية للب�ل, بينما مت ا�ضتبعاد حاالت التعاطي املزمن. مت فح�ص امل�ضاعفات القلبية عن طريق جهاز 
تخطيط القلب الكهربائي وتخطيط القلب عن طريق ال�ضدر بال�ضدى. النتائج: كان هناك اجمايل 230 مري�ضًا ي�ضكل�ن ن�ضبة )%5.9( من 
جميع املر�ضى ِمن َمن يتعاط�ن االأمفيتامني وكانت فح��ضات الب�ل عندهم اإيجابية, من بني ه�ؤالء كان عدد 32 )%13.9(مري�ضًا منهم 
االأمفيتامني  م�ضتخدمي  )%51.7( مري�ضًا من   119 عدد  الذك�ر. وكان هناك جمماًل  )%85.2( مري�ضًا من   196 الع�رسين وعدد  �ضن  دون 
ومركبات امليثامفيتامني, بينما كان 111 )%48.3( مري�ضًا ِمن َمن ي�ضتخدم�ن االأمفيتامينات اإ�ضافًة اإىل امل�رفني اأو البنزوديازيبينات. 
اأظهرت النتائج اأن اأكرث م�ضاعفات القلب �ضي�عًا ح�ضب تخطيط القلب هي ت�رّسع القلب اجليبي بن�ضبة )%43.0(, يليها ت�رّسع القلب اجليبي 
امل�ضاحب با�ضتطالة فرتة QT الفا�ضلة )%34.3(. كان مت��ضط الكرياتني كاينيز-MB مقداره 4.3 ـ± 35.9 وحدة والرتوب�نني 0.2 ـ± 0.6 
مليليرت. مت اإدخال ما جمم�عه )%26.1( 60 مري�ضًا اإىل وحدة العناية املركزة. وكانت نتائج فح��ضات القلب بال�ضدى طبيعية الأغلبية 
ه�ؤالء املر�ضى )%83.3(. كما كان مت��ضط قطر جذر ال�رسيان االأبهر مقداره 2.8 ± 27.2 مليمرت. وقد وجدت ت�ض�هات متعلقة بجذر ال�رسيان 
االأبهر يف 10 مر�ضى )%16.7(, ت�يف ثالثة منهم الحقا. اخلال�صة: وفقًا لهذه النتائج ي�ضتنتج اأن امل�ضاعفات القلبية هي االأكرث �ضي�عًا بني 
املر�ضى االإيرانيني الذين ي�ضي�ؤون تعاطي االأمفيتامينات, لكن بالرغم من ذلك فاإن اأغلبية املر�ضى كان نتائج فح��ضات القلب بالتخطيط 
الكهربائي وبال�ضدى عندهم طبيعية.
بال�ضدى؛ القلب  تخطيط  القلب؛  دقات  ت�رّسع  الدم�ية؛  واالأوعية  القلب  ت�ض�هات  الكيميائية؛  امل�اد  تعاطي  االأمفيتامينات؛  املفتاحية:   الكلمات 
تخطيط القلب الكهربائي؛ اإيران.
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Psychoactive drug dependence/abusehas become an increasing problem worldwide, with adverse physical, familial, social, mental 
and financial consequences.1 In Iran, patterns of 
drug abuse have changed immensely in recent years, 
with drug use shifting from traditional opioids to 
new artificial opioids.2 Moreover, the incidence 
of drug poisoning and toxicity due to the abuse of 
psychoactive drugs—such as amphetamines—has 
increased among younger individuals.3 Acute use of 
amphetamines results in increased brain activity and 
a feeling of euphoria; however, chronic use of these 
compounds can lead to psychological dependency, 
loss of appetite, depression, aggressive behaviour, 
irritability and sleep, memory and mood disorders.1 
In addition, amphetamine abuse may lead to increased 
stimulation of the sympathetic nervous system, which 
could in turn lead to hypertension, hyperthermia, 
subarachnoid haemorrhage and ventricular dysrhyth-
mias, sometimes resulting in death.4
Depending on the type and form of the drug, 
central nervous system stimulants can be imbibed 
orally, injected, smoked or snorted. Direct injection of 
the stimulant into the blood stream or inhalation into 
the lungs enables the more rapid onset of the drug’s 
effects.5 The stimulants increase the synaptic concen-
tration of neural mediators (especially adrenaline, 
dopamine and serotonin), stimulating these mediators 
and inhibiting their reuptake. Amphetamine com-
pounds stimulate the central and peripheral nervous 
systems, increasing catecholamine secretion and 
inhibiting their reuptake. At the synapse, the catecho-
lamines lead to excessive cardiac stimulation and an 
increased heart rate.1 Amphetamine compounds have 
good oral absorption and a wide range of distribution 
sizes (3–33 L/kg); they are primarily metabolised by 
the liver and excreted in acidic urine.1
Cardiac complications are an important issue 
in the context of drug toxicity. Hypertension is the 
most common cardiovascular result of central 
nervous system stimulants.1 With oral amphetamines, 
systolic and diastolic blood pressure increases, while 
heart rate decreases. The cardiovascular effect of the 
laevus isomer in amphetamines is greater than that 
of the dexter isomer.6 Chest pains, dysrhythmias, 
acute coronary syndrome, acute cardiac infarctions, 
vasospasms, irreversible cardiomyopathy and acute 
pulmonary oedema are among the cardiovascular 
manifestations of toxicity arising from psycho- 
active drugs.7 This study aimed to evaluate cardio-
vascular complications among Iranian patients who 
abuse amphetamines.
Methods
This descriptive cross-sectional study took place 
between April 2014 and April 2015 among 3,870 
patients referred to the Toxicology Emergency 
Department of Baharlou Hospital, Tehran University 
of Medical Sciences, Tehran, Iran. Only those 
individuals with positive urine drug screening test 
results and a history of acute amphetamine abuse 
were included in the study. Patients with a history 
of underlying cardiovascular disease or a family 
history of cardiac disease and those with diabetes 
mellitus, proven hypertension or hyperlipidaemia 
were excluded from the study. In addition, chronic 
drug users without any evidence of recent abuse were 
not included.
A predesigned checklist was used to collect existing 
data, including the demographic characteristics and 
laboratory and clinical findings of the patients. Rapid 
urine drug screening tests (ACON Laboratories 
Inc., San Diego, California, USA) were performed. 
Following this, blood samples were taken from each 
patient. Patients were evaluated using cardiac and 
vital sign monitoring, routine laboratory examin-
ations and cardiac biomarker tests, including levels of 
troponin I (AiA-360 benchtop immunoassay analyser, 
Tosoh Bioscience, San Francisco, California, USA) and 
creatinine kinase (CK)-MB (Architect System STAT 
CK-MB chemiluminescent microparticle immuno-
assay, Abbott Diagnostics, Wiesbaden, Germany). 
Normal cut-off troponin I and CK-MB levels were set 
at 0.1 ng/mL and 24.0 U/mL respectively, as per the 
manufacturers’ recommendations. 
Cardiac complications were evaluated via 
electrocardiography (ECG) and transthoracic echo-
cardiography (TTE). All ECG and TTE scans were 
performed by an emergency physician. Each patient 
underwent three ECG recordings to measure the 
following variables: heart rate, rhythm, QT interval 
(intervals of >0.44 milliseconds were considered 
prolonged), supraventricular and ventricular arrhyth-
mias, atrioventricular and ventricular cardiac blocks, 
tall T-waves and myocardial ischaemia (i.e. ST 
segment and T-wave changes).8 Tachycardia was 
defined as a heart rate of >100 beats/minute.1 
Moreover, for patients admitted to the Intensive Care 
Unit (ICU) due to tachycardia or very abnormal ECG 
findings, additional echocardiography was performed 
to measure their ejection fraction (EF), regional wall 
motion abnormalities, aortic root diameter (ARD), 
cardiac wall size (including right ventricular end-
diastolic volume, left ventricle end-systolic volume, 
left ventricular end-diastolic volume, left ventricular 
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end-diastolic pressure [LVEDP], left ventricular end-
diastolic diameter [LVEDD] and left ventricle end-
systolic diameter [LVESD]) and other abnormalities.
Data were analysed using the Statistical Package 
for the Social Sciences (SPSS), Version 22 (IBM 
Corp., Chicago, Illinois, USA). Chi-squared, analysis 
of variance, Student’s t-test, Mann-Whitney U and 
Kruskal-Wallis tests were performed, as appropriate. 
A P value of <0.050 was considered statistically 
significant. Interquartile ranges and correlations were 
also calculated.
Ethical approval for this study was granted by 
the Tehran University of Medical Sciences. Prior to 
being enrolled in the study, all of the patients gave 
conscious informed consent. If the competency of 
the patient was in doubt, informed consent was given 
by a relative. Data confidentiality and security were 
ensured throughout the study period.
Results
Of the 3,870 patients referred to the Toxicology 
Emergency Department during the study period, 
460 (11.9%) had a history of amphetamine use. 
Among these, 395 cases (10.2%) had positive urine 
drug screening results; however, 165 cases (4.3%) 
were excluded due to a history of chronic abuse. 
Therefore, a total of 230 patients (5.9%) were enrolled 
in the study. The mean age of the participants was 
34.4 ± 11.4 years (range: 15–68 years old) and the 
majority were male (85.2%). Amphetamines were 
smoked by 161 patients (70.0%), taken orally by 
20 patients (8.7%), injected by 10 patients (4.3%) and 
taken via a combination of methods by 39 patients 
(17.0%). A total of 119 patients (51.7%) used ampheta-
mines in combination with methamphetamine com-
pounds while 111 (48.3%) used amphetamines with 
morphine or benzodiazepines. The referral time to 
the emergency ward was ≤6 hours of use for 174 
patients (75.7%) and >6 hours of use for 56 patients 
(24.3%) [Table 1].
The ECG results were normal for 104 patients 
(45.2%). Sinus tachycardia was observed in 99 patients 
(43.0%), while 34.3% of patients had sinus tachycardia 
plus a prolonged QT interval. Arrhythmias were 
Table 1: Characteristics of patients referred to a 
toxicology emergency department following acute 
amphetamine abuse in Tehran, Iran (N = 230)
Characteristic n (%)
Age in years
<20 32 (13.9)
21–30 86 (37.4)
31–40 62 (27.0)
41–50 33 (14.3)
>50 17 (7.4)
Gender
Male 196 (85.2)
Female 34 (8.7)
Drugs taken
Amphetamine and methamphetamine 119 (51.7)
Amphetamine and morphine/benzodiazepines 111 (48.3)
Method of drug administration
Smoking 161 (70.0)
Oral 20 (8.7)
Injection 10 (4.3)
Combination 39 (17.0)
Time to admission in hours
0–6 174 (75.7)
>6 56 (24.3)
Agitation 
Present 131 (57.0)
Absent 99 (43.0)
ECG finding*
Normal 104 (45.2)
Sinus tachycardia 99 (43.0)
Sinus tachycardia plus prolonged QT interval 79 (34.3)
Arrhythmia 8 (3.5)
Arrhythmia plus first-degree atrioventricular 
block 
6 (2.6)
Tall T-wave 4 (1.7)
Arrhythmia, ST segment elevation plus 
anterior MI
4 (1.7)
Arrhythmia plus ST segment elevation 3 (1.3)
ST segment elevation 1 (0.4)
Anterior MI 1 (0.4)
Mean BP ± SD
Systolic BP in mmHg 129.9 ± 4.2
Diastolic BP in mmHg 82.1 ± 3.4
Mean HR in beats/minute 109.1 ± 9.3
Mean CK-MB level in U/mL 35.9 ± 4.3
Mean troponin I level in ng/mL 0.6 ± 0.2
ECG = electrocardiography; MI = myocardial infarction; BP = blood 
pressure; SD = standard deviation; HR = heart rate; CK-MB = creatinine 
kinase-MB.
*Patients with more than one abnormality have been included in 
several categories. 
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observed in eight patients (3.5%). Other cardiac 
abnormalities included arrhythmias plus a first-degree 
atrioventricular block (2.6%), tall T-waves (1.7%), 
arrhythmias, ST segment elevation plus anterior 
myocardial infarctions (1.7%), arrhythmias plus ST 
segment elevation (1.3%), anterior myocardial infarc-
tions (0.4%) and ST segment elevation (0.4%). Mean 
CK-MB and troponin I levels were 35.9 ± 4.3 U/mL 
and 0.6 ± 0.2 ng/mL, respectively [Table 1]. For the 
patients with arrhythmias, this complication was 
followed by ventricular tachycardia, premature atrial 
contractions, paroxysmal supraventricular tachycardia 
and premature ventricular contractions. 
A total of 60 patients were admitted to the ICU; 
of these, the majority were 21–30 years old (28.3%). 
Mean LVEDD and LVESD measurements were 
45.4 ± 4.4 mm (range: 39–56 mm) and 29.2 ± 3.5 mm 
(range: 22–36 mm), respectively. Mean LVEDD 
measurements were significantly higher in patients 
who were >50 years old (P = 0.034). Although there 
was no significant difference in LVESD measurements 
among age groups (P = 0.433), the highest value was 
observed in patients between 41–50 years old. The 
mean LVEDP value was 8.5 ± 3.5 mmHg (range: 
6–10 mmHg) and there was a significant difference 
in LVEDP value according to age group (P = 0.042), 
with the highest values noted in patients <20 years old 
and >50 years old. The highest mean EF was observed 
in patients <20 years old and the lowest mean EF was 
found in patients aged 31–40 years old (P = 0.012). 
The mean ARD was 27.2 ± 2.8 mm (range: 22–32 mm) 
with a significant difference according to age group 
(P = 0.032). Patients >50 years of age had the highest 
mean ARD and patients <20 years old had the lowest 
mean ARD [Table 2].
Of the 60 patients admitted to the ICU, the 
majority had normal echocardiography findings 
(83.3%). However, four patients (6.7%) had left ventri-
cular systolic and/or diastolic dysfunction. The most 
common abnormality of the cardiac valves was 
related to the mitral valve (MV); 21.7% of patients 
had mild MV regurgitation, 3.3% had moderate MV 
regurgitation and 3.3% had MV prolapse. Tricuspid 
regurgitation and mild aortic regurgitation were 
found in 3.3% and 1.7% of patients, respectively. 
Right ventricular function was abnormal in two 
patients (3.3%). Anterior akinaesia and pulmonary 
hypertension plus cor pulmonale were each reported 
Table 2: Selected echocardiographic measurements according to age group among patients admitted to an intensive 
care unit following acute amphetamine abuse in Tehran, Iran (N = 60)
Mean ± SD Age in years P value
<20 
(n = 6)
21–30 
(n = 17)
31–40 
(n = 15)
41–50 
(n = 5)
>50 
(n = 17)
RVESv in mL/m2 24.3 ± 3.2 25.1 ± 3.4 28.1 ± 3.4 26.6 ± 3.5 26.2 ± 3.7 0.144
LVEDD in mm 43.2 ± 4.4 43.5 ± 4.3 46.6 ± 4.5 43.8 ± 4.6 47.7 ± 4.7 0.034
LVESD in mm 28.8 ± 3.2 29.8 ± 3.4 29.1 ± 3.6 30.4 ± 3.5 28.6 ± 3.7 0.433
EF in % 54.2 ± 5.8 50.6 ± 5.6 48.2 ± 5.5 50.1 ± 5.5 48.8 ± 5.2 0.012
LVEDP in mmHg 8.8 ± 3.4 8.3 ± 3.7 8.4 ± 3.5 8.4 ± 3.2 8.8 ± 3.5 0.042
ARD in mm 24.8 ± 2.4 26.3 ± 2.7 25.7 ± 2.6 28.8 ± 2.9 29.7 ± 3.3 0.032
SD = standard deviation; RVESv = right ventricle end-systolic volume; LVEDD = left ventricular end-diastolic diameter; LVESD = left ventricle end-
systolic diameter; EF = ejection fraction; LVEDP = left ventricular end-diastolic pressure; ARD = aortic root diameter.
Table 3: Cardiac function according to echocardio-
graphy among patients admitted to an intensive care 
unit following acute amphetamine abuse in Tehran, 
Iran (N = 60)
Finding n (%)
Normal 50 (83.3)
LVS or LVD dysfunction alone 5 (8.3)
LVS and LVD dysfunction combined 1 (1.7)
Anterior akinaesia 3 (5.0)
PAH plus cor pulmonale 1 (1.7)
RV function
Normal 58 (96.7)
Abnormal 2 (3.3)
MV dysfunction
Normal 43 (71.7)
Mild regurgitation 13 (21.7)
Moderate regurgitation 2 (3.3)
Prolapse 2 (3.3)
Other valvular dysfunctions
None 57 (95.0)
Tricuspid regurgitation 2 (3.3)
Mild aortic regurgitation 1 (1.7)
LVS = left ventricular systolic; LVD = left ventricular diastolic; 
PAH = pulmonary artery hypertension; RV = right ventricular; 
MV = mitral valve.
Elham Bazmi, Farinaz Mousavi, Leila Giahchin, Tahmineh Mokhtari and Behnam Behnoush
Clinical and Basic Research | e35
in 1.7% of patients, respectively [Table 3]. Right 
ventricular wall movement abnormalities was noted 
only among patients who were 30–39 years old and 
>50 years old. In addition, abnormal right ventricular 
function was seen only among those aged 30–39 years 
old [Table 4].
Unfortunately, 10 patients (16.7%) died among 
those admitted to the ICU. While left ventricular 
end-diastolic volume and diameter values were 
normal in all of the admitted patients, two living 
patients (3.3%) and one deceased patient (1.7%) had 
abnormal interventricular systolic diameters. More-
over, abnormal EF was noted in four of the patients 
who died (6.7%) and three living patients (5.0%), with 
abnormal EF significantly more prevalent among the 
deceased patients (P = 0.011). The ARD was abnormal 
in seven living patients and three deceased patients 
(11.7% versus 5.0%; P = 0.211) [Table 5]. The frequency 
of severe right ventricle end-diastolic volume 
disorder was higher among the deceased patients 
than the survivors (10.0% versus 2.0%) [Table 6]. 
Discussion
According to the findings of the current study, amphe-
tamine abuse occurred mostly among individuals aged 
21–40 years old (64.4%), with fewer participants being 
<20 years old (13.9%) or >41 years old (21.7%). Other 
studies have shown that drug abuse is more prevalent 
among young people.9,10 Barooni et al. found that 18.5% 
of young adults who went to coffee shops in Tehran 
had a history of psychoactive drug abuse, in the form 
of ecstasy abuse.3 As with the present study, previous 
research has indicated that the mean age of drug 
abusers is low in Iran.11,12 A study of drug abuse cases 
in Taiwan reported a mean age of 26.7 years among 
those who abused drugs for the first time.13 In a study 
of methamphetamine-related fatalities in Australia, 
Kaye et al. found that the mean age of patients was 32.7 
years and that 77% were male.14 In the current study, 
the vast majority of the subjects were male (85.2%). 
Other researchers have also reported more frequent 
drug abuse practices among men.13,15,16 
In the current study, approximately half of the 
patients exclusively used amphetamine and meth-
amphetamine, while the rest used other drugs in 
combination with amphetamines. In addition, most 
patients administered the drugs via inhalation. Kaye 
et al. found that 89% of their subjects had used 
drugs other from methamphetamine, including 
benzodiazepines (41%) and morphine (36%).14 More-
over, administration of amphetamine is usually 
reported to be intravenous.14,17 In the current study, 
10 patients (4.3%) died after being admitted to the 
ICU, presumably due to drug-related toxicity. Knudsen 
et al. reported an amphetamine-related mortality rate 
of 12.3% among γ-hydroxybutyrate poisoning cases 
in Sweden.18 
Troponin I and CK-MB levels were very high among 
amphetamine users in the present study, indicating 
Table 4: Right ventricular wall mobility and function 
abnormalities according to age group among patients 
admitted to an intensive care unit following acute 
amphetamine abuse in Tehran, Iran (N = 60)
n (%)
Right ventricular wall 
motion abnormalities
Right ventricular 
function
Normal Abnormal Normal Abnormal
Age in years
<20 6 (10.0) 0 (0.0) 6 (10.0) 0 (0.0)
21–29 17 (28.3) 0 (0.0) 17 (28.3) 0 (0.0)
30–39 13 (21.7) 2 (3.3) 13 (21.7) 2 (3.3)
40–41 5 (8.3) 0 (0.0) 5 (8.3) 0 (0.0)
>50 16 (26.7) 1 (1.7) 17 (28.3) 0 (0.0)
Total 57 (95.0) 3 (5.0) 58 (96.7) 2 (3.3)
Table 5: Echocardiographic findings among deceased and 
living patients admitted to an intensive care unit following 
acute amphetamine abuse in Tehran, Iran (N = 60)
Finding n (%) P value
Living 
patients 
(n = 50)
Deceased 
patients 
(n = 10)
LVEDv 0 (0.0) 0 (0.0) -
IVSD 2 (3.3) 1 (1.7) 0.427
LVEDD 0 (0.0) 0 (0.0) -
Abnormal EF 3 (5.0) 4 (6.7) 0.011
ARD 7 (11.7) 3 (5.0) 0.212
LVEDv = left ventricle end-diastolic volume; IVSD = interventricular 
systolic diameter, LVEDD = left ventricular end-diastolic diameter; 
EF = ejection fraction; ARD = aortic root diameter.
Table 6: Frequency of right ventricle end-diastolic 
volume disorder among deceased and living patients 
admitted to an intensive care unit in Tehran, Iran, 
following acute amphetamine abuse (N = 60)
Classification n (%)
Living patients 
(n = 50)
Deceased patients 
(n = 10)
Normal 42 (84.0) 9 (90.0)
Fair 7 (14.0) 0 (0.0)
Moderate 0 (0.0) 0 (0.0)
Severe 1 (2.0) 1 (10.0)
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cardiac damage; these findings were consistent with 
those of various previously published research.19–22 
In a case report, Khattab et al. described a 54-year-old 
man with chest pains after amphetamine use, 
increased troponin I and CK-MB levels and complete 
obstruction of the left circumflex coronary artery due 
to acute thrombosis.23 The most commonly observed 
abnormal ECG findings in the current study were 
sinus tachycardia (43.0%) and sinus tachycardia 
plus a prolonged QT interval (34.3%). Haning et al. 
observed prolonged QT intervals among 27.2% of 
patients abusing methamphetamines in the USA.24 
Other researchers have reported various arrhythmias 
associated with the use of amphetamines or other 
psychoactive drugs, such as QT interval fluctuations, 
right bundle branch block and ST segment changes, 
particularly ST segment elevation.25–28 Westover et al. 
found a significant relationship between acute myo-
cardial infarction and amphetamine abuse.29 More-
over, Kaye et al. found use of amphetamines to 
be associated with high pathological cardiac risk; 
however, this was possibly due to the presence of pre-
existing chronic disorders and hence not limited to 
amphetamine use.14
According to TTE findings in the current study, 
left ventricular systolic dysfunction was noted in 
three cases, abnormal EF in seven cases and abnormal 
ARD in 10 cases; additionally, right ventricle end-
diastolic volume disorder was observed among both 
living and deceased patients admitted to the ICU. 
To the best of the authors’ knowledge, no similar 
studies have been published in which amphetamine 
users were evaluated using echocardiographical 
parameters. However, various case reports have 
shown different cardiac abnormalities following 
abuse of amphetamine, such as reverse Takotsubo 
cardiomyopathy.30 Yeo et al. reported that cardio-
myopathy was related to methamphetamine use 
among young adults in Hawaii.31 Moreover, Wijetunga 
et al. found that 84% of crystal methamphetamine 
users had cardiomyopathy and global ventricular 
disorders.32 In another study, Maeno et al. found 
that methamphetamine use directly led to cellular 
hypertrophy and could potentially result in disorders 
of cardiac function among adult rats.33 Varner et al. 
demonstrated that methamphetamine administration 
could significantly change cardiovascular responses 
and lead to severe cardiac pathology; moreover, they 
also showed that methamphetamine elicited biphasic 
heart rate responses consisting of initial bradycardia 
followed by tachycardia.34 According to a review of 
methamphetamine-induced cardiac complications by 
Paratz et al., dilated, hypertrophic and stress cardio-
myopathies are the most common methamphet- 
amine-associated cardiomyopathies.35 Additionally, 
intranasal administration of d-amphetamine report-
edly lead to a more rapid response compared with 
oral administration.5
This study is subject to certain limitations. 
Although the statistical significance of the findings in 
this study could not be determined due to the small 
sample size, these findings may pave the way for future 
research focusing on echocardiography findings 
among amphetamine users. Also, as there are few 
studies in the current literature on this topic, it was 
difficult to compare the findings of this study with 
those of previous research. In the current study, most 
of the subjects were referred to the hospital in the 
acute phase of drug abuse and the researchers did 
not have access to each patient’s prior medical history 
relating to heart disease. As such, distinguishing heart 
problems due to drug abuse from those resulting 
from pre-existing cardiac disorders was not possible. 
In addition, most of the patients who were admitted 
did not consent to undergo echocardiography. 
Another limitation of this study was the lack of a 
control group with which to compare results. More 
studies are needed to assess the true pathogenicity of 
amphetamine abuse.
Conclusion
Although the majority of patients had normal TTE 
and ECG scans, cardiac complications were common 
among Iranian patients who abuse amphetamines, 
particularly sinus tachycardia and sinus tachycardia 
plus prolonged QT intervals. Emergency physicians 
should therefore be aware of these as potential cardio-
vascular complications of acute amphetamine abuse.
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